Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis

Autoimmunity

Volumn 39, Issue 8, 2006, Pages 651-662

  Baranzini, Sergio E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Central nervous system; Combination therapy; Dynamical system modeling; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONCEPTUAL FRAMEWORK; DATA ANALYSIS; DISEASE PREDISPOSITION; HUMAN; INFORMATION; LIFE; MATHEMATICS; MODEL; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; PHYSICS; PHYSIOLOGY; STEADY STATE; SYMPTOM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; COMPUTATIONAL BIOLOGY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, THEORETICAL; MULTIPLE SCLEROSIS; SYSTEMS BIOLOGY;

EID: 33845716141     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930601061686     Document Type: Article

References (114)

1. Ahn, AC and Tewari, M and Poon, CS and Phillips, RS. (2006) The limits of reductionism in medicine: Could systems biology offer an alternative? PLoS Med, 3(6), pp. e208.
2. Bar-Yam, Y.(2005) Making things work: Solving complex problems in a complex world. Cambridge, CA: Knowledge Press.
3. Hauser, SL and Goodin, DS.(2005) Multiple sclerosis and other demyelinating diseases. In Harrison's principles in internal medicine16th ed. (pp. 2461-2471). New York: McGraw Hill.
4. Confavreux, C and Vukusic, S. (2006) Natural history of multiple sclerosis: A unifying concept Brain, 129(Pt 3), pp. 606-616.
5. Sadovnick, AD and Armstrong, H and Rice, GP and Bulman, D and Hashimoto, L and Paty, DW and Hashimoto, SA and Warren, S and Hader, W and Murray, TJ and (1993) A population-based study of multiple sclerosis in twins: Update Ann Neurol, 33(3), pp. 281-285.
6. Mumford, CJ and Wood, NW and Kellar-Wood, H and Thorpe, JW and Miller, DH and Compston, DA. (1994) The British Isles survey of multiple sclerosis in twins Neurology, 44(1), pp. 11-15.
7. Steinman, L and Zamvil, SS. (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis Ann Neurol, 60(1), pp. 12-21.
8. Hart, BA and Amor, S. (2003) The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system Curr Opin Neurol, 16(3), pp. 375-383.
9. Ruddle, NH and Bergman, CM and McGrath, KM and Lingenheld, EG and Grunnet, ML and Padula, SJ and Clark, RB. (1990) An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis J Exp Med, 172(4), pp. 1193-1200.
10. Selmaj, KW and Raine, CS. (1995) Experimental autoimmune encephalomyelitis: Immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors Neurology, 45(6 Suppl 6), pp. S44-S49.
11. van Oosten, BW and Barkhof, F and Truyen, L and Boringa, JB and Bertelsmann, FW and von Blomberg, BM and Woody, JN and Hartung, HP and Polman, CH. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 Neurology, 47(6), pp. 1531-1534.
12. Elliott, MJ and Maini, RN and Feldmann, M and Long-Fox, A and Charles, P and Katsikis, P and Brennan, FM and Walker, J and Bijl, H and Ghrayeb, J and (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha Arthritis Rheum, 36(12), pp. 1681-1690.
13. Hale, G and Swirsky, DM and Hayhoe, FG and Waldmann, H. (1983) Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans Mol Biol Med, 1(3), pp. 321-334.
14. Heit, W and Bunjes, D and Wiesneth, M and Schmeiser, T and Arnold, R and Hale, G and Waldmann, H and Heimpel, H. (1986) Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation Br J Haematol, 64(3), pp. 479-486.
15. Lim, SH and Hale, G and Marcus, RE and Waldmann, H and Baglin, TP. (1993) CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura Br J Haematol, 84(3), pp. 542-544.
16. Moreau, T and Thorpe, J and Miller, D and Moseley, I and Hale, G and Waldmann, H and Clayton, D and Wing, M and Scolding, N and Compston, A. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis Lancet, 344(8918), pp. 298-301.
17. Moreau, T and Coles, A and Wing, M and Isaacs, J and Hale, G and Waldmann, H and Compston, A. (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis Brain, 119(Pt 1), pp. 225-237.
18. Jacobs, L and O'Malley, J and Freeman, A and Ekes, R. (1981) Intrathecal interferon reduces exacerbations of multiple sclerosis Science, 214(4524), pp. 1026-1028.
19. Compston, A and Sawcer, S. (2002) Genetic analysis of multiple sclerosis Curr Neurol Neurosci Rep, 2(3), pp. 259-266.
20. Cooperative TTMSG. (2001) A meta-analysis of genomic screens in multiple sclerosis Mult Scler, 7(1), pp. 3-11.
21. Cooperative TTMSG, GAMES. (2003) A meta-analysis of whole genome linkage screens in multiple sclerosis J Neuroimmunol, 143(1-2), pp. 39-46.
22. Barcellos, LF and Oksenberg, JR and Green, AJ and Bucher, P and Rimmler, JB and Schmidt, S and Garcia, ME and Lincoln, RR and Pericak-Vance, MA and Haines, JL and (2002) Genetic basis for clinical expression in multiple sclerosis Brain, 125(Pt 1), pp. 150-158.
23. Haines, JL and Terwedow, HA and Burgess, K and Pericak-Vance, MA and Rimmler, JB and Martin, ER and Oksenberg, JR and Lincoln, R and Zhang, DY and Banatao, DR and (1998) Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The multiple sclerosis genetics group Hum Mol Genet, 7(8), pp. 1229-1234.
24. Chabas, D and Baranzini, SE and Mitchell, D and Bernard, CC and Rittling, SR and Denhardt, DT and Sobel, RA and Lock, C and Karpuj, M and Pedotti, R and (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease Science, 294(5547), pp. 1731-1735.
25. Lock, C and Hermans, G and Pedotti, R and Brendolan, A and Schadt, E and Garren, H and Langer-Gould, A and Strober, S and Cannella, B and Allard, J and (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nat Med, 8(5), pp. 500-508.
26. Graumann, U and Reynolds, R and Steck, AJ and Schaeren-Wiemers, N. (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult Brain Pathol, 13(4), pp. 554-573.
27. Lindberg, RL and De Groot, CJ and Certa, U and Ravid, R and Hoffmann, F and Kappos, L and Leppert, D. (2004) Multiple sclerosis as a generalized CNS disease-comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS J Neuroimmunol, 152(1-2), pp. 154-167.
28. Baranzini, SE and Oksenberg, JR and Hauser, SL. (2002) New insights into the genetics of multiple sclerosis J Rehabil Res Dev, 39(2), pp. 201-209.
29. Achiron, A and Gurevich, M and Friedman, N and Kaminski, N and Mandel, M. (2004) Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity Ann Neurol, 55(3), pp. 410-417.
30. Mandel, M and Gurevich, M and Pauzner, R and Kaminski, N and Achiron, A. (2004) Autoimmunity gene expression portrait: Specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus Clin Exp Immunol, 138(1), pp. 164-170.
31. Satoh, J and Nakanishi, M and Koike, F and Miyake, S and Yamamoto, T and Kawai, M and Kikuchi, S and Nomura, K and Yokoyama, K and Ota, K and (2005) Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis Neurobiol Dis, 18(3), pp. 537-550.
32. Satoh, J and Nakanishi, M and Koike, F and Onoue, H and Aranami, T and Yamamoto, T and Kawai, M and Kikuchi, S and Nomura, K and Yokoyama, K and (2006) T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients J Neuroimmunol, 174(1-2), pp. 108-118.
33. van Baarsen, LG and van der Pouw Kraan, TC and Kragt, JJ and Baggen, JM and Rustenburg, F and Hooper, T and Meilof, JF and Fero, MJ and Dijkstra, CD and Polman, CH and (2006) A subtype of multiple sclerosis defined by an activated immune defense program Genes Immun.
34. Matejuk, A and Hopke, C and Dwyer, J and Subramanian, S and Jones, RE and Bourdette, DN and Vandenbark, AA and Offner, H. (2003) CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis J Neurosci Res, 73(5), pp. 667-678.
35. Mycko, MP and Papoian, R and Boschert, U and Raine, CS and Selmaj, KW. (2003) cDNA microarray analysis in multiple sclerosis lesions: Detection of genes associated with disease activity Brain, 126(Pt 5), pp. 1048-1057.
36. Mycko, MP and Papoian, R and Boschert, U and Raine, CS and Selmaj, KW. (2004) Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis Clin Neurol Neurosurg, 106(3), pp. 223-229.
37. Tajouri, L and Mellick, AS and Ashton, KJ and Tannenberg, AE and Nagra, RM and Tourtellotte, WW and Griffiths, LR. (2003) Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis Brain Res Mol Brain Res, 119(2), pp. 170-183.
38. Dutta, R and McDonough, J and Yin, X and Peterson, J and Chang, A and Torres, T and Gudz, T and Macklin, WB and Lewis, DA and Fox, RJ and (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients Ann Neurol, 59(3), pp. 478-489.
39. Liebman, MN. (2002) Biomedical informatics: The future for drug development Drug Discov Today, 7(20 Suppl), pp. S197-S203.
40. Bolouri, H and Davidson, EH. (2002) Modeling transcriptional regulatory networks Bioessays, 24(12), pp. 1118-1129.
41. Wolfson, C and Confavreux, C. (1985) A Markov model of the natural history of multiple sclerosis Neuroepidemiology, 4(4), pp. 227-239.
42. Confavreux, C and Vukusic, S and Moreau, T and Adeleine, P. (2000) Relapses and progression of disability in multiple sclerosis N Engl J Med, 343(20), pp. 1430-1438.
43. Volterra, V.(1931) Variations and fluctuations of the number of individuals in animal species living together. In Animal ecology. New York: McGraw-Hill.
44. Chen, KC and Calzone, L and Csikasz-Nagy, A and Cross, FR and Novak, B and Tyson, JJ. (2004) Integrative analysis of cell cycle control in budding yeast Mol Biol Cell, 15(8), pp. 3841-3862.
45. Wolfram, S.(2002) A new kind of science. Champaign, IL: Wolfram Media Inc.
46. Kauffman, SA.(1993) The origins of order: Self-organization and selection in evolution. New York: Oxford University Press.
47. Huang, WX and Huang, P and Link, H and Hillert, J. (1999) Cytokine analysis in multiple sclerosis by competitive RT-PCR: A decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression [comment] Mult Scler, 5(5), pp. 342-348.
48. Lucchinetti, C and Bruck, W and Parisi, J and Scheithauer, B and Rodriguez, M and Lassmann, H. (2000) Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination Ann Neurol, 47(6), pp. 707-717.
49. Jeffery, DR. (2004) Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis Neurology, 63(12 Suppl 6), pp. S41-S46.
50. Stuve, O and Youssef, S and Weber, MS and Nessler, S and von Budingen, HC and Hemmer, B and Prod'homme, T and Sobel, RA and Steinman, L and Zamvil, SS. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity J Clin Invest, 116(4), pp. 1037-1044.
51. Weinstock-Guttman, B and Bakshi, R. (2004) Combination therapy for multiple sclerosis: The treatment strategy of the future? CNS Drugs, 18(12), pp. 777-792.
52. Chang, TT and Jabs, C and Sobel, RA and Kuchroo, VK and Sharpe, AH. (1999) Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis J Exp Med, 190(5), pp. 733-740.
53. Suh, WK and Gajewska, BU and Okada, H and Gronski, MA and Bertram, EM and Dawicki, W and Duncan, GS and Bukczynski, J and Plyte, S and Elia, A and (2003) The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses Nat Immunol, 4(9), pp. 899-906.
54. Lev, N and Barhum, Y and Melamed, E and Offen, D. (2004) Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice Neurosci Lett, 359(3), pp. 139-142.
55. Ye, Q and Press, B and Kissler, S and Yang, XF and Lu, L and Bassing, CH and Sleckman, BP and Jansson, M and Panoutsakopoulou, V and Trimble, LA and (2002) T cell costimulation through CD28 depends on induction of the Bcl-xgamma isoform: Analysis of Bcl-xgamma-deficient mice J Exp Med, 196(1), pp. 87-95.
56. Calida, DM and Constantinescu, C and Purev, E and Zhang, GX and Ventura, ES and Lavi, E and Rostami, A. (2001) Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice J Immunol, 166(2), pp. 723-726.
57. Furlan, R and Martino, G and Galbiati, F and Poliani, PL and Smiroldo, S and Bergami, A and Desina, G and Comi, G and Flavell, R and Su, MS and (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination J Immunol, 163(5), pp. 2403-2409.
58. Fife, BT and Huffnagle, GB and Kuziel, WA and Karpus, WJ. (2000) CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis J Exp Med, 192(6), pp. 899-905.
59. Tran, EH and Kuziel, WA and Owens, T. (2000) Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor Eur J Immunol, 30(5), pp. 1410-1415.
60. Murphy, CA and Hoek, RM and Wiekowski, MT and Lira, SA and Sedgwick, JD. (2002) Interactions between hemopoietically derived TNF and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain J Immunol, 169(12), pp. 7054-7062.
61. Teige, A and Teige, I and Lavasani, S and Bockermann, R and Mondoc, E and Holmdahl, R and Issazadeh-Navikas, S. (2004) CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis J Immunol, 172(1), pp. 186-194.
62. Hoek, RM and Ruuls, SR and Murphy, CA and Wright, GJ and Goddard, R and Zurawski, SM and Blom, B and Homola, ME and Streit, WJ and Brown, MH and (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200) Science, 290(5497), pp. 1768-1771.
63. Abromson-Leeman, S and Maverakis, E and Bronson, R and Dorf, ME. (2001) CD40-mediated activation of T cells accelerates, but is not required for, encephalitogenic potential of myelin basic protein-recognizing T cells in a model of progressive experimental autoimmune encephalomyelitis Eur J Immunol, 31(2), pp. 527-538.
64. Ford, ML and Onami, TM and Sperling, AI and Ahmed, R and Evavold, BD. (2003) CD43 modulates severity and onset of experimental autoimmune encephalomyelitis J Immunol, 171(12), pp. 6527-6533.
65. Grewal, IS and Foellmer, HG and Grewal, KD and Wang, H and Lee, WP and Tumas, D and Janeway, CA, Jr. and Flavell, RA. (2001) CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis Immunity, 14(3), pp. 291-302.
66. Tompkins, SM and Padilla, J and Dal Canto, MC and Ting, JP and Van Kaer, L and Miller, SD. (2002) De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis J Immunol, 168(8), pp. 4173-4183.
67. Linker, RA and Maurer, M and Gaupp, S and Martini, R and Holtmann, B and Giess, R and Rieckmann, P and Lassmann, H and Toyka, KV and Sendtner, M and (2002) CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation Nat Med, 8(6), pp. 620-624.
68. Hilliard, BA and Mason, N and Xu, L and Sun, J and Lamhamedi-Cherradi, SE and Liou, HC and Hunter, C and Chen, YH. (2002) Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation J Clin Invest, 110(6), pp. 843-850.
69. Liu, L and Huang, D and Matsui, M and He, TT and Hu, T and Demartino, J and Lu, B and Gerard, C and Ransohoff, RM. (2006) Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3 -/- mice with experimental autoimmune encephalomyelitis J Immunol, 176(7), pp. 4399-4409.
70. Bakker, AB and Hoek, RM and Cerwenka, A and Blom, B and Lucian, L and McNeil, T and Murray, R and Phillips, LH and Sedgwick, JD and Lanier, LL. (2000) DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming Immunity, 13(3), pp. 345-353.
71. Agrawal, A and Dillon, S and Denning, TL and Pulendran, B. (2006) ERK1 -/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis J Immunol, 176(10), pp. 5788-5796.
72. Abdul-Majid, KB and Stefferl, A and Bourquin, C and Lassmann, H and Linington, C and Olsson, T and Kleinau, S and Harris, RA. (2002) Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis Scand J Immunol, 55(1), pp. 70-81.
73. Dubois, B and Masure, S and Hurtenbach, U and Paemen, L and Heremans, H and van den Oord, J and Sciot, R and Meinhardt, T and Hammerling, G and Opdenakker, G and (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions J Clin Invest, 104(11), pp. 1507-1515.
74. Ikushima, H and Kanaoka, M and Kojima, S. (2003) Cutting edge: Requirement for growth hormone-releasing hormone in the development of experimental autoimmune encephalomyelitis J Immunol, 171(6), pp. 2769-2772.
75. Teuscher, C and Poynter, ME and Offner, H and Zamora, A and Watanabe, T and Fillmore, PD and Zachary, JF and Blankenhorn, EP. (2004) Attenuation of Th1 effector cell responses and susceptibility to experimental allergic encephalomyelitis in histamine H2 receptor knockout mice is due to dysregulation of cytokine production by antigen-presenting cells Am J Pathol, 164(3), pp. 883-892.
76. Samoilova, EB and Horton, JL and Chen, Y. (1998) Experimental autoimmune encephalomyelitis in intercellular adhesion molecule-1-deficient mice Cell Immunol, 190(1), pp. 83-89.
77. Dong, C and Juedes, AE and Temann, UA and Shresta, S and Allison, JP and Ruddle, NH and Flavell, RA. (2001) ICOS co-stimulatory receptor is essential for T-cell activation and function Nature, 409(6816), pp. 97-101.
78. Krakowski, M and Owens, T. (1996) Interferon-gamma confers resistance to experimental allergic encephalomyelitis Eur J Immunol 26(7), pp. 1641-1646.
79. Tran, EH and Prince, EN and Owens, T. (2000) IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines J Immunol, 164(5), pp. 2759-2768.
80. Teige, I and Treschow, A and Teige, A and Mattsson, R and Navikas, V and Leanderson, T and Holmdahl, R and Issazadeh-Navikas, S. (2003) IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis J Immunol, 170(9), pp. 4776-4784.
81. Bettelli, E and Das, MP and Howard, ED and Weiner, HL and Sobel, RA and Kuchroo, VK. (1998) IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice J Immunol, 161(7), pp. 3299-3306.
82. Becher, B and Durell, BG and Noelle, RJ. (2002) Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12 J Clin Invest, 110(4), pp. 493-497.
83. Zhang, GX and Yu, S and Gran, B and Li, J and Siglienti, I and Chen, X and Calida, D and Ventura, E and Kamoun, M and Rostami, A. (2003) Role of IL-12 receptor beta 1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis J Immunol, 171(9), pp. 4485-4492.
84. Zhang, GX and Gran, B and Yu, S and Li, J and Siglienti, I and Chen, X and Kamoun, M and Rostami, A. (2003) Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system J Immunol, 170(4), pp. 2153-2160.
85. Shi, FD and Takeda, K and Akira, S and Sarvetnick, N and Ljunggren, HG. (2000) IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells J Immunol, 165(6), pp. 3099-3104.
86. Petitto, JM and Streit, WJ and Huang, Z and Butfiloski, E and Schiffenbauer, J. (2000) Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice Neurosci Lett, 285(1), pp. 66-70.
87. Mendel, I and Katz, A and Kozak, N and Ben-Nun, A and Revel, M. (1998) Interleukin-6 functions in autoimmune encephalomyelitis: A study in gene-targeted mice Eur J Immunol, 28(5), pp. 1727-1737.
88. Sahrbacher, UC and Lechner, F and Eugster, HP and Frei, K and Lassmann, H and Fontana, A. (1998) Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis Eur J Immunol, 28(4), pp. 1332-1338.
89. Buch, T and Uthoff-Hachenberg, C and Waisman, A. (2003) Protection from autoimmune brain inflammation in mice lacking IFN-regulatory factor-1 is associated with Th2-type cytokines Int Immunol, 15(7), pp. 855-859.
90. Suen, WE and Bergman, CM and Hjelmstrom, P and Ruddle, NH. (1997) A critical role for lymphotoxin in experimental allergic encephalomyelitis J Exp Med, 186(8), pp. 1233-1240.
91. Du, C and Sriram, S. (2002) Increased severity of experimental allergic encephalomyelitis in lyn -/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system J Immunol, 168(6), pp. 3105-3112.
92. Huang, DR and Wang, J and Kivisakk, P and Rollins, BJ and Ransohoff, RM. (2001) Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis J Exp Med, 193(6), pp. 713-726.
93. Delarasse, C and Daubas, P and Mars, LT and Vizler, C and Litzenburger, T and Iglesias, A and Bauer, J and Della Gaspera, B and Schubart, A and Decker, L and (2003) Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice J Clin Invest, 112(4), pp. 544-553.
94. Brennan, M and Gaur, A and Pahuja, A and Lusis, AJ and Reynolds, WF. (2001) Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis J Neuroimmunol, 112(1-2), pp. 97-105.
95. Lyons, JA and Ramsbottom, MJ and Cross, AH. (2002) Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein Eur J Immunol, 32(7), pp. 1905-1913.
96. Hilliard, B and Samoilova, EB and Liu, TS and Rostami, A and Chen, Y. (1999) Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice: Roles of NF-kappa B in the activation and differentiation of autoreactive T cells J Immunol, 163(5), pp. 2937-2943.
97. Carboni, S and Aboul-Enein, F and Waltzinger, C and Killeen, N and Lassmann, H and Pena-Rossi, C. (2003) CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis J Neuroimmunol, 145(1-2), pp. 1-11.
98. Ndhlovu, LC and Ishii, N and Murata, K and Sato, T and Sugamura, K. (2001) Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis J Immunol, 167(5), pp. 2991-2999.
99. Copray, S and Kust, B and Emmer, B and Lin, MY and Liem, R and Amor, S and de Vries, H and Floris, S and Boddeke, E. (2004) Deficient p75 low-affinity neurotrophin receptor expression exacerbates experimental allergic encephalomyelitis in C57/BL6 mice J Neuroimmunol, 148(1-2), pp. 41-53.
100. Raijmakers, R and Vogelzangs, J and Raats, J and Panzenbeck, M and Corby, M and Jiang, H and Thibodeau, M and Haynes, N and Van Venrooij, WJ and Pruijn, GJ and (2006) Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice J Comp Neurol, 498(2), pp. 217-226.
101. Graesser, D and Solowiej, A and Bruckner, M and Osterweil, E and Juedes, A and Davis, S and Ruddle, NH and Engelhardt, B and Madri, JA. (2002) Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice J Clin Invest, 109(3), pp. 383-392.
102. Malipiero, U and Frei, K and Spanaus, KS and Agresti, C and Lassmann, H and Hahne, M and Tschopp, J and Eugster, HP and Fontana, A. (1997) Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice Eur J Immunol, 27(12), pp. 3151-3160.
103. Tan, SL and Zhao, J and Bi, C and Chen, XC and Hepburn, DL and Wang, J and Sedgwick, JD and Chintalacharuvu, SR and Na, S. (2006) Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C theta-deficient mice J Immunol, 176(5), pp. 2872-2879.
104. Natarajan, C and Muthian, G and Barak, Y and Evans, RM and Bright, JJ. (2003) Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis J Immunol, 171(11), pp. 5743-5750.
105. Harroch, S and Furtado, GC and Brueck, W and Rosenbluth, J and Lafaille, J and Chao, M and Buxbaum, JD and Schlessinger, J. (2002) A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions Nat Genet, 32(3), pp. 411-414.
106. Chen, L and Brosnan, CF. (2006) Exacerbation of experimental autoimmune encephalomyelitis in P2X7R -/- mice: Evidence for loss of apoptotic activity in lymphocytes J Immunol, 176(5), pp. 3115-3126.
107. Chitnis, T and Najafian, N and Benou, C and Salama, AD and Grusby, MJ and Sayegh, MH and Khoury, SJ. (2001) Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis J Clin Invest, 108(5), pp. 739-747.
108. Prinz, M and Garbe, F and Schmidt, H and Mildner, A and Gutcher, I and Wolter, K and Piesche, M and Schroers, R and Weiss, E and Kirschning, CJ and (2006) Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis J Clin Invest, 116(2), pp. 456-464.
109. Korner, H and Riminton, DS and Strickland, DH and Lemckert, FA and Pollard, JD and Sedgwick, JD. (1997) Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting J Exp Med, 186(9), pp. 1585-1590.
110. Liu, J and Marino, MW and Wong, G and Grail, D and Dunn, A and Bettadapura, J and Slavin, AJ and Old, L and Bernard, CC. (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination Nat Med, 4(1), pp. 78-83.
111. Bachmann, R and Eugster, HP and Frei, K and Fontana, A and Lassmann, H. (1999) Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice Am J Pathol, 154(5), pp. 1417-1422.
112. Suvannavejh, GC and Lee, HO and Padilla, J and Dal Canto, MC and Barrett, TA and Miller, SD. (2000) Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis Cell Immunol, 205(1), pp. 24-33.
113. Lu, W and Bhasin, M and Tsirka, SE. (2002) Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis J Neurosci, 22(24), pp. 10781-10789.
114. Korn, T and Fischer, KD and Girkontaite, I and Kollner, G and Toyka, K and Jung, S. (2003) Vav1-deficient mice are resistant to MOG-induced experimental autoimmune encephalomyelitis due to impaired antigen priming J Neuroimmunol, 139(1-2), pp. 17-26.